Cidara is pursuing a balanced infectious disease-focused development strategy intended to transform standards of care and save lives.

Phase 1

Phase 2

Phase 3

Treatment of Candidemia and Invasive Candidiasis

Phase 3 Planned Mid-2018

65%

Prophylaxis for Candida, PCP and Aspergillus in alloBMT

Phase 3 Planned Mid-2018

65%

Research

IND Enabling

Phase 1

Small Molecule Treatment Gram (-) Bacteria

with

IND-Enabling

30%

ADC

Large Molecule Treatment and Prophylaxis Gram (-) Bacteria

Research

20%

GET IMPORTANT NEWS AND UPDATES BY EMAIL